Modality
Peptide
MOA
SGLT2i
Target
IL-13
Pathway
Sphingolipid
Epilepsy
Development Pipeline
Preclinical
~Oct 2014
→ ~Jan 2016
Phase 1
~Apr 2016
→ ~Jul 2017
Phase 2
~Oct 2017
→ ~Jan 2019
Phase 3
Apr 2019
→ Oct 2030
Phase 3Current
NCT06347638
50 pts·Epilepsy
2023-01→2030-09·Terminated
NCT08906348
183 pts·Epilepsy
2020-03→2030-10·Recruiting
NCT04778592
2,556 pts·Epilepsy
2022-01→2025-10·Terminated
+1 more trial
3,133 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2025-10-235mo agoEMA Filing· Epilepsy
2025-10-255mo agoPh3 Readout· Epilepsy
2030-09-054.4y awayPh3 Readout· Epilepsy
2030-10-164.5y awayPh3 Readout· Epilepsy
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P3
Complet…
P3
Recruit…
P3
Termina…
P3
Termina…
Catalysts
EMA Filing
2025-10-23 · 5mo ago
Epilepsy
Ph3 Readout
2025-10-25 · 5mo ago
Epilepsy
Ph3 Readout
2030-09-05 · 4.4y away
Epilepsy
Ph3 Readout
2030-10-16 · 4.5y away
Epilepsy
RecruitingCompletedTerminated|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06347638 | Phase 3 | Epilepsy | Terminated | 50 | CR |
| NCT08906348 | Phase 3 | Epilepsy | Recruiting | 183 | PASI75 |
| NCT04778592 | Phase 3 | Epilepsy | Terminated | 2556 | ORR |
| NCT06745621 | Phase 3 | Epilepsy | Completed | 344 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Motazanubrutinib | Biogen | Preclinical | CD38 |